The observation that CAV1 inhibition modulated by 6‐mercaptopurine, daidzin, and statins enhances the efficacy of bortezomib in vitro and in vivo highlights the translational significance of these FDA‐approved drugs in improving MM outcomes. Here, CAV1 is linked to Miyoshi myopathy.